Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 study evaluating pharmacokinetics, safety, and tolerability of PF-06651600 in hepatic impairment and healthy volunteers has completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Impairment

Drugs mentioned

• PF-06651600 (PF-06651600)

Snippet

Sponsor: Pfizer | Conditions: Hepatic Impairment, Healthy Participants | Phase 1 | Status: COMPLETED | Results posted: 2021-04-08